|
EP0547544B1
(de)
*
|
1991-12-18 |
1997-03-12 |
Hoechst Aktiengesellschaft |
Verfahren zur Gewinnung von insulinhaltigen Lösungen
|
|
ATE203998T1
(de)
*
|
1993-04-27 |
2001-08-15 |
Hoechst Ag |
Amorphe monosphärische formen von insulinderivaten
|
|
DE19512484A1
(de)
|
1995-04-04 |
1996-10-17 |
Bayer Ag |
Kohlenhydratmodifizierte Cytostatika
|
|
ATE264871T1
(de)
*
|
1996-07-26 |
2004-05-15 |
Aventis Pharma Gmbh |
Insulinderivate mit erhöhter zinkbindung
|
|
DE19652713C2
(de)
*
|
1996-12-18 |
2001-11-22 |
Aventis Pharma Gmbh |
Verfahren zur Reinigung von Insulin und Insulinderivaten durch Chromatographie an stark saurem Kationenaustauscher
|
|
TR200001050T2
(tr)
*
|
1997-10-24 |
2000-08-21 |
Eli Lilly And Company |
Çözünmez insülin bileşimleri
|
|
US6444641B1
(en)
|
1997-10-24 |
2002-09-03 |
Eli Lilly Company |
Fatty acid-acylated insulin analogs
|
|
DE19825447A1
(de)
|
1998-06-06 |
1999-12-09 |
Hoechst Marion Roussel De Gmbh |
Neue Insulinanaloga mit erhöhter Zinkbildung
|
|
DE19838097A1
(de)
|
1998-08-24 |
2000-03-02 |
Hoechst Marion Roussel De Gmbh |
Verfahren zur chromatographischen Reinigung von Insulinen
|
|
US6933272B1
(en)
|
1998-09-22 |
2005-08-23 |
Erik Helmerhorst |
Use of non-peptidyl compounds for the treatment of insulin related ailments
|
|
DE60120372T2
(de)
*
|
2000-03-24 |
2007-07-05 |
Genentech Inc., San Francisco |
Verwendung von insulin zur behandlung von knorpelkrankheiten
|
|
US7316999B2
(en)
|
2000-06-02 |
2008-01-08 |
Novo Nordisk A/S |
Glucose dependent release of insulin from glucose sensing insulin derivatives
|
|
DE10114178A1
(de)
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
|
|
FR2822834B1
(fr)
*
|
2001-04-02 |
2005-02-25 |
Flamel Tech Sa |
Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
|
|
JP2005508895A
(ja)
*
|
2001-08-28 |
2005-04-07 |
イーライ・リリー・アンド・カンパニー |
Ｇｌｐ−１および基礎インスリンの予備混合物
|
|
WO2003031432A1
(en)
|
2001-10-12 |
2003-04-17 |
Novo Nordisk A/S |
Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
|
|
MXPA04003569A
(es)
*
|
2001-10-19 |
2004-07-23 |
Lilly Co Eli |
Mezclas bifasicas de glp-1 e insulina.
|
|
HRP20040551A2
(en)
*
|
2001-12-20 |
2004-10-31 |
Lilly Co Eli |
Insulin molecule having protracted time action
|
|
US7774816B2
(en)
*
|
2002-04-23 |
2010-08-10 |
Rovi Technologies Corporation |
Conflict manager for a video recorder
|
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
|
FR2843117B1
(fr)
*
|
2002-07-30 |
2004-10-15 |
Flamel Tech Sa |
Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
|
|
US20040138099A1
(en)
*
|
2002-11-29 |
2004-07-15 |
Draeger Eberhard Kurt |
Insulin administration regimens for the treatment of subjects with diabetes
|
|
EP1615698B1
(en)
|
2003-04-11 |
2010-09-29 |
High Point Pharmaceuticals, LLC |
New amide derivatives and pharmaceutical use thereof
|
|
CA2518776A1
(en)
*
|
2003-04-29 |
2004-11-11 |
Eli Lilly And Company |
Insulin analogs having protracted time action
|
|
FR2860516B1
(fr)
*
|
2003-10-03 |
2006-01-13 |
Flamel Tech Sa |
Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
|
|
MXPA06005581A
(es)
|
2003-11-20 |
2006-08-11 |
Novo Nordisk As |
Formulaciones de peptidos que contienen propilenglicol que son optimas para la produccion y uso en dispositivos de inyeccion.
|
|
FR2862536B1
(fr)
*
|
2003-11-21 |
2007-11-23 |
Flamel Tech Sa |
Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
|
|
FR2873040B1
(fr)
|
2004-07-19 |
2007-11-30 |
Flamel Technologies Sa |
Formulation colloidale d'insuline longue action et sa preparation
|
|
US7833513B2
(en)
|
2004-12-03 |
2010-11-16 |
Rhode Island Hospital |
Treatment of Alzheimer's Disease
|
|
CN103110635A
(zh)
|
2005-07-04 |
2013-05-22 |
海波因特制药有限责任公司 |
组胺h3受体拮抗剂
|
|
EP1910317B1
(en)
|
2005-07-20 |
2013-07-03 |
Eli Lilly And Company |
1-amino linked compounds
|
|
US7863329B2
(en)
|
2005-11-17 |
2011-01-04 |
Eli Lilly And Company |
Glucagon receptor antagonists, preparation and therapeutic uses
|
|
FR2896164B1
(fr)
*
|
2006-01-18 |
2008-07-04 |
Flamel Technologies Sa |
Formulation colloidale d'insuline longue action et sa preparation
|
|
EP2241327A1
(en)
|
2006-03-15 |
2010-10-20 |
Novo Nordisk A/S |
Mixtures of Amylin and Insulin
|
|
US8394842B2
(en)
|
2006-03-28 |
2013-03-12 |
High Point Pharmaceuticals, Llc |
Benzothiazoles having histamine H3 receptor activity
|
|
CA2649111C
(en)
|
2006-04-24 |
2013-09-10 |
Eli Lilly And Company |
Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
|
|
HRP20120227T1
(hr)
|
2006-05-29 |
2012-04-30 |
High Point Pharmaceuticals |
3-(1,3-benzodioksol-5-il)-6-(4-ciklopropilpiperazin-1-il)piridazin, njegove soli i solvati te njegova uporaba kao antagonista histaminskog h3 receptora
|
|
DE102006031962A1
(de)
*
|
2006-07-11 |
2008-01-17 |
Sanofi-Aventis Deutschland Gmbh |
Amidiertes Insulin Glargin
|
|
DE102006031955A1
(de)
*
|
2006-07-11 |
2008-01-17 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
|
|
US7417517B2
(en)
*
|
2006-07-13 |
2008-08-26 |
Motorola, Inc. |
Method and apparatus for a communications filter
|
|
WO2008145730A1
(en)
|
2007-06-01 |
2008-12-04 |
Novo Nordisk A/S |
Stable non-aqueous pharmaceutical compositions
|
|
EP2164466A1
(en)
|
2007-06-01 |
2010-03-24 |
Novo Nordisk A/S |
Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
|
|
WO2009021955A1
(en)
|
2007-08-13 |
2009-02-19 |
Novo Nordisk A/S |
Rapid acting insulin analogues
|
|
CN107115523A
(zh)
|
2007-11-16 |
2017-09-01 |
诺沃—诺迪斯克有限公司 |
包含glp‑1肽或毒蜥外泌肽‑4和基础胰岛素肽的药物组合物
|
|
DE102008025008A1
(de)
|
2008-05-24 |
2009-11-26 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
|
DE102008003566A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
|
DE102008003568A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
|
EP2229406B1
(de)
|
2008-01-09 |
2015-04-22 |
Sanofi-Aventis Deutschland GmbH |
Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
|
|
DE102008025007A1
(de)
|
2008-05-24 |
2009-11-26 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
|
BRPI0907371A2
(pt)
*
|
2008-01-09 |
2015-11-24 |
Sanofi Aventis Deutschland |
derivados de insulina com um perfil de tempo-ação muito retardado
|
|
PL219335B1
(pl)
*
|
2008-07-04 |
2015-04-30 |
Inst Biotechnologii I Antybiotyków |
Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
|
|
DE102008051834A1
(de)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
|
DE102009038210A1
(de)
|
2009-08-20 |
2011-03-03 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
|
PL2349324T3
(pl)
|
2008-10-17 |
2018-02-28 |
Sanofi-Aventis Deutschland Gmbh |
Kombinacja insuliny i agonisty GLP-1
|
|
DE102008053048A1
(de)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
|
EA020496B1
(ru)
|
2008-11-21 |
2014-11-28 |
ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Производное адамантилбензамида, фармацевтическая композиция, включающая его, и его применение
|
|
EP2451472A1
(de)
*
|
2009-07-06 |
2012-05-16 |
Sanofi-Aventis Deutschland GmbH |
Hitze- und schüttelstabile insulinzubereitungen
|
|
WO2011003823A1
(de)
|
2009-07-06 |
2011-01-13 |
Sanofi-Aventis Deutschland Gmbh |
Langsamwirkende insulinzubereitungen
|
|
MY159865A
(en)
|
2009-07-06 |
2017-02-15 |
Sanofi Aventis Deutschland |
Aqueous insulin preparations containing methionine
|
|
MX2012001141A
(es)
|
2009-07-31 |
2012-03-29 |
Sanofi Aventis Deutschland |
Composicion de insulina de accion prolongada.
|
|
AU2010277559B2
(en)
|
2009-07-31 |
2016-08-11 |
Sanofi-Aventis Deutschland Gmbh |
Prodrugs comprising an insulin linker conjugate
|
|
SG10201500871TA
(en)
|
2009-11-13 |
2015-04-29 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a glp-1 agonist and methionine
|
|
PL2498802T3
(pl)
|
2009-11-13 |
2015-06-30 |
Sanofi Aventis Deutschland |
Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę
|
|
AU2011202239C1
(en)
*
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
|
PL2611458T3
(pl)
|
2010-08-30 |
2017-02-28 |
Sanofi-Aventis Deutschland Gmbh |
Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
|
|
EP2438930A1
(en)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an exendin linker conjugate
|
|
EA201390796A1
(ru)
|
2011-01-20 |
2014-07-30 |
Зилэнд Фарма А/С |
Применение ацилированного аналога глюкагона
|
|
EP2670368A4
(en)
|
2011-02-03 |
2015-04-15 |
Pharmedica Ltd |
NEW ORAL DISSOLUTION FILMS FOR INSULIN DELIVERY FOR THE TREATMENT OF DIABETES
|
|
CN102219851B
(zh)
|
2011-05-09 |
2012-05-30 |
甘李药业有限公司 |
甘精胰岛素结晶的制备方法
|
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
BR112014002986A2
(pt)
|
2011-08-10 |
2017-06-13 |
Adocia |
composição sob a forma de uma solução injetável, e formulação de dose única
|
|
CA2846413C
(en)
|
2011-08-29 |
2021-11-02 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
|
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
|
US10350139B2
(en)
|
2011-10-25 |
2019-07-16 |
Corning Incorporated |
Pharmaceutical glass packaging assuring pharmaceutical sterility
|
|
WO2013063283A1
(en)
|
2011-10-25 |
2013-05-02 |
Corning Incorporated |
Delamination resistant pharmaceuticals glass containers containing active pharmaceutical ingredients
|
|
EP2814461B1
(fr)
|
2012-01-09 |
2019-07-24 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue
|
|
PL222975B1
(pl)
|
2012-05-23 |
2016-09-30 |
Inst Biotechnologii I Antybiotyków |
Analog insuliny lub jego farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna o przedłużonym działaniu terapeutycznym oraz zastosowanie analogu insuliny
|
|
WO2013173923A1
(en)
|
2012-05-25 |
2013-11-28 |
Diamedica, Inc. |
Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
|
|
SI2854841T1
(sl)
|
2012-06-04 |
2017-06-30 |
Diamedica Inc. |
Glikozilacijske izooblike humanega tkivnega kalikreina-1
|
|
US20150314003A2
(en)
|
2012-08-09 |
2015-11-05 |
Adocia |
Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
|
|
FR3001896B1
(fr)
|
2013-02-12 |
2015-07-03 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
|
|
FR3001895B1
(fr)
|
2013-02-12 |
2015-07-03 |
Adocia |
Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
|
|
CN104994864B
(zh)
*
|
2012-12-19 |
2018-05-29 |
沃克哈特有限公司 |
包含人胰岛素或其类似物或衍生物的稳定水性组合物
|
|
TWI780236B
(zh)
|
2013-02-04 |
2022-10-11 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
|
RU2705797C2
(ru)
|
2013-04-03 |
2019-11-12 |
Санофи |
Лечение сахарного диабета с помощью составов инсулинов длительного действия
|
|
US9700485B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9707153B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9713572B2
(en)
|
2013-04-24 |
2017-07-25 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9839579B2
(en)
|
2013-04-24 |
2017-12-12 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9707155B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9717648B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9849066B2
(en)
|
2013-04-24 |
2017-12-26 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9717649B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9700486B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
US9707154B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
SG11201604710XA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
|
JP6735674B2
(ja)
|
2014-01-09 |
2020-08-05 |
サノフイＳａｎｏｆｉ |
インスリンアスパルトの安定化された医薬製剤
|
|
CN111658604A
(zh)
|
2014-01-09 |
2020-09-15 |
赛诺菲 |
胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
|
|
LT3229828T
(lt)
|
2014-12-12 |
2023-06-12 |
Sanofi-Aventis Deutschland Gmbh |
Insulino glargino/liksisenatido fiksuoto santykio kompozicija
|
|
CN104688677B
(zh)
*
|
2015-02-05 |
2018-02-09 |
通化东宝药业股份有限公司 |
一种稳定的甘精胰岛素注射液及其制备方法
|
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患治療
|
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患之治療
|
|
AR107560A1
(es)
|
2016-02-24 |
2018-05-09 |
Lilly Co Eli |
Compuesto que disminuye la glucosa en la sangre
|
|
FR3052072A1
(fr)
|
2016-06-07 |
2017-12-08 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
|
EP3329930A1
(en)
|
2016-12-05 |
2018-06-06 |
Nuritas Limited |
Pharmaceuctical compositions
|
|
EP4129321A1
(en)
|
2016-12-05 |
2023-02-08 |
Nuritas Limited |
Compositions comprising peptide wkdeagkplvk
|
|
KR20190122706A
(ko)
|
2017-03-09 |
2019-10-30 |
다이어메디카 인코포레이티드 |
조직 칼리크레인 1의 투약 형태
|
|
FR3070264A1
(fr)
|
2017-08-24 |
2019-03-01 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris de 5,8 a 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
|
WO2019110625A1
(fr)
|
2017-12-06 |
2019-06-13 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
|
FR3083088B1
(fr)
|
2018-06-29 |
2020-10-02 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
|
FR3083089A1
(fr)
|
2018-06-29 |
2020-01-03 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
|
EP3740229B1
(fr)
|
2017-12-07 |
2025-04-09 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
|
KR20240171196A
(ko)
|
2017-12-07 |
2024-12-06 |
아도시아 |
pI가 5.8 내지 8.5인 적어도 1종의 기저 인슐린, 및 카복실산염 전하 및 소수성 라디칼을 보유하는 코-폴리아미노산을 포함하는 pH 7의 주사용 용액
|
|
KR20200106892A
(ko)
|
2017-12-07 |
2020-09-15 |
아도시아 |
pI가 5.8 내지 8.5인 적어도 1종의 기저 인슐린, 및 카복실산염 전하 및 소수성 라디칼을 보유하는 코-폴리아미노산을 포함하는 pH 7의 주사용 용액
|
|
US20210214412A1
(en)
*
|
2018-04-16 |
2021-07-15 |
University Of Utah Research Foundation |
Glucose-responsive insulin
|
|
WO2019243628A1
(fr)
|
2018-06-22 |
2019-12-26 |
Adocia |
Composition injectable a ph 7 comprenant un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes et au moins une insuline basale presentant au moins un effet prandial et un effet basal
|
|
FR3084585B1
(fr)
|
2018-08-03 |
2020-11-06 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un compose amphiphile porteur de radicaux hydrophobes
|
|
KR102666154B1
(ko)
|
2018-08-08 |
2024-05-20 |
주식회사 대웅제약 |
지속형 인슐린 아날로그 및 그 복합체
|
|
WO2020115334A1
(fr)
|
2018-12-07 |
2020-06-11 |
Adocia |
Procede de preparation d'une composition stable sous forme d'une solution aqueuse injectable
|
|
US20200179489A1
(en)
|
2018-12-07 |
2020-06-11 |
Adocia |
Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol
|
|
KR20200080748A
(ko)
|
2018-12-27 |
2020-07-07 |
주식회사 폴루스 |
음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
|
|
KR20200080747A
(ko)
|
2018-12-27 |
2020-07-07 |
주식회사 폴루스 |
인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
|
|
KR20200082618A
(ko)
|
2018-12-31 |
2020-07-08 |
주식회사 폴루스 |
인슐린 과발현용 램프 태그 및 이를 이용한 인슐린의 제조방법
|
|
WO2020245470A1
(fr)
|
2019-06-07 |
2020-12-10 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5, du liraglutide et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
|
TW202434620A
(zh)
|
2019-07-31 |
2024-09-01 |
美商美國禮來大藥廠 |
鬆弛素(relaxin)類似物及其使用方法
|
|
CN113105536B
(zh)
|
2020-09-11 |
2023-07-18 |
美药星（南京）制药有限公司 |
一种新甘精胰岛素原及其制备甘精胰岛素的方法
|
|
CN114805610B
(zh)
*
|
2022-06-23 |
2022-10-04 |
北京惠之衡生物科技有限公司 |
一种高表达甘精胰岛素前体的重组基因工程菌及其构建方法
|